| Andrea E Laverdure, LPC | |
|
113 Main Ave E, Rolla, ND 58367 | |
| (701) 477-8272 | |
| (701) 477-8271 |
| Full Name | Andrea E Laverdure |
|---|---|
| Gender | Female |
| Speciality | Counselor |
| Location | 113 Main Ave E, Rolla, North Dakota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588848741 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101Y00000X | Counselor | 41211198 (North Dakota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Andrea E Laverdure, LPC Po Box 650, Devils Lake, ND 58301-0650 Ph: (701) 477-8272 | Andrea E Laverdure, LPC 113 Main Ave E, Rolla, ND 58367 Ph: (701) 477-8272 |
News Archive
Radient Pharmaceuticals Corporation, a US-based pharmaceutical company through its wholly-owned subsidiary AMDL Diagnostics, Inc. (ADI) announced today it has entered into an exclusive 5-year marketing and distribution agreement with Grifols USA, LLC.
In his latest Kaiser Health News column - done in collaboration with The New Republic, Jonathan Cohn writes: "Over the last week or so, as passage seemed ever more likely, Republicans moved from denial to anger.
Credicorp filed an Annual Report on Form 20-F for the year ended December 31, 2009 with the Securities and Exchange Commission ("SEC"). The 2009 Form 20-F includes audited consolidated financial statements of Credicorp and its subsidiaries as of December 31, 2008 and 2009 and for the years ended December 31, 2007, 2008 and 2009 under IFRS.
The brain adds new cells during puberty to help navigate the complex social world of adulthood, two Michigan State University neuroscientists report in the current issue of the Proceedings of the National Academy of Sciences.
Centocor Ortho Biotech Inc. today announced that it has acquired RespiVert Ltd., a privately held drug discovery company focused on developing small-molecule, inhaled therapies for the treatment of pulmonary diseases. The company's lead compounds, RV-568 and RV-1088, narrow spectrum kinase inhibitors with a unique profile of anti-inflammatory activities, are progressing into clinical development as potential first-in-class treatments for moderate to severe asthma, Chronic Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis (CF).
› Verified 4 days ago
Ms. Wanda Jean Lamotte, LSW, LAC Counselor Medicare: Not Enrolled in Medicare Practice Location: 113 Main Ave E, Rolla, ND 58367 Phone: 701-477-8272 Fax: 701-477-8281 | |
Mckenzie M Day, LAC Counselor Medicare: Not Enrolled in Medicare Practice Location: 1102 Main Ave W, Rolla, ND 58367 Phone: 701-477-9050 | |
Molly Rae Allery, MA Counselor Medicare: Not Enrolled in Medicare Practice Location: 1102 Main Ave W, Rolla, ND 58329 Phone: 701-477-9050 | |
Patricia J Sitter, M.ED, LAPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 113 Main Ave E, Rolla, ND 58367 Phone: 701-477-8272 Fax: 701-477-8181 | |
Susan M. Davis, L.A.C. Counselor Medicare: Not Enrolled in Medicare Practice Location: 113 Main Ave E, Rolla, ND 58367 Phone: 701-477-8272 Fax: 701-477-8281 | |
Cynthia Bercier, LAC, LSW Counselor Medicare: Not Enrolled in Medicare Practice Location: 113 Main Ave E, Rolla, ND 58367 Phone: 701-477-8272 Fax: 701-477-8281 |